Quantcast
Get breaking news alerts via email

Click here to manage your alerts
(Rick Egan | The Salt Lake Tribune) Dr. Jeff Campsen, surgical director of kidney transplants at the University of Utah (left) talks about Andres Galvan's kidney transplant, which is believed to be the first kidney transplant in Utah using an organ from a donor with hepatitis C and into a patient with hepatitis C. Thursday, July 31, 2014
Utah hepatitis C patient gets kidney with same virus
Medicine » Doctors say the organ worked immediately; recipient can expect a long life.
First Published Jul 31 2014 05:32 pm • Last Updated Jul 31 2014 09:53 pm

A West Jordan man who has hepatitis C went home from University of Utah Hospital Thursday with a new kidney, the first Utah patient to receive such an organ from a donor with the same virus.

"It’s a new opportunity to live," said Andres Galvan, 61, through a translator at a U. press briefing.

Join the Discussion
Post a Comment

Galvan had been undergoing dialysis for kidney failure for more than two years and had been on the kidney transplant list for a year.

When he agreed to accept a kidney from a deceased out-of-state donor with hepatitis C, the transplant team bumped him to the top of the list. Patients typically wait two to three years for organs from healthy donors.

Galvan received the new kidney on Sunday, said surgeon Jeff Campsen.

"The kidney worked immediately. He’s off of dialysis," Campsen said. "All expectations, all clinical signs are that he is just going to do wonderfully."

In the past, such a patient would have been considered a poor candidate for transplant because the liver — and the new kidney — would continue to be damaged by the hepatitis C virus.

Then, last year, new game-changing drugs that can cure hepatitis C were introduced. The drugs are 90 percent effective and lack the side effects of the old drugs, Campsen said.

Doctors at the U. will evaluate Galvan after three months. If he is healed and tolerating the new kidney well, U. doctors can prescribe Sovaldi, one of the new drugs.

Campsen said Galvan can expect a long life.


story continues below
story continues below

The U. transplant team will duplicate the treatment with other patients, he said. "As we’re successful, we’ll expand."

President Barack Obama signed the Hope Act last year, paving the way for transplanting organs from HIV-positive donors into patients with the HIV virus, which causes AIDS. The U. has no plans to do such transplants soon, however.

"We’ve had conversations about it, but have no plans to work on it now," said Campsen. "Hepatitis C was the first step. You get excited about this stuff, but we have to be cautious."

kmoulton@sltrib.com

Twitter: @KristenMoulton



Copyright 2014 The Salt Lake Tribune. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Top Reader Comments Read All Comments Post a Comment
Click here to read all comments   Click here to post a comment


About Reader Comments


Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
Staying Connected
Videos
Jobs
Contests and Promotions
  • Search Obituaries
  • Place an Obituary

  • Search Cars
  • Search Homes
  • Search Jobs
  • Search Marketplace
  • Search Legal Notices

  • Other Services
  • Advertise With Us
  • Subscribe to the Newspaper
  • Access your e-Edition
  • Frequently Asked Questions
  • Contact a newsroom staff member
  • Access the Trib Archives
  • Privacy Policy
  • Missing your paper? Need to place your paper on vacation hold? For this and any other subscription related needs, click here or call 801.204.6100.